- Record: found
- Abstract: found
- Article: found
STARD3: A New Biomarker in HER2-Positive Breast Cancer.
Massimo Lodi
1
,
2
,
3 ,
Laetitia Voilquin
3 ,
Fabien Alpy
3 ,
Sébastien Molière
1
,
2
,
3 ,
Nathalie Reix
1 ,
Carole Mathelin
1
,
2
,
3 ,
Marie-Pierrette Chenard
1 ,
Catherine-Laure Tomasetto
3
Jan 05 2023
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Pathological complete response (pCR) after neoadjuvant systemic treatment (NST) is an important prognostic factor in HER2-positive breast cancer. The majority of HER2-positive breast cancers are amplified at the HER2 gene locus, several genes are co-amplified with HER2, and a subset of them are co-expressed. The STARD3 gene belongs to the HER2 amplicon, and its role as a predictive marker was never addressed. The objective of this study was to investigate the predictive value of STARD3 protein expression on NST pathological response in HER2-positive breast cancer. In addition, we studied the prognostic value of this marker.